

ITEM 7.01 Regulation FD Disclosures

On April 19, 2017, CytRx Corporation ("we," "us," "our" and the "company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has reached an agreement with the company regarding preparations for a New Drug Application (NDA) submission for aldoxorubicin as a treatment for soft tissue sarcomas. A copy of the press release is attached as Exhibit 99.1 to this Report and incorporated herein by reference.

Also on April 19, 2017, we hosted a webcast, as described in the press release, to discuss the regulatory pathway. A replay of the webcast will be posted on our website: www.cytrx.com.

The information in this Item 7.01 and Exhibit 99.1 to this Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index which immediately follows the signature page thereof and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTRX CORPORATION

April 19, 2017 By: /s/ STEVEN A. KRIEGSMAN

Steven A. Kriegsman

Title: Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release of CytRx Corporation issued on April 19, 2017